Palisade Bio Inc
PALI
Company Profile
Business description
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Contact
7750 El Camino Real
Suite 2A
CarlsbadCA92009
USAT: +1 858 704-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
The ‘other’ AI chip behemoth that might just be getting started
The magnitude of growth at Broadcom continues to astound us.
stocks
Why ANZ changes aren’t just about cutting costs
The banking major needs to prevent key product offerings from falling further behind the competition.
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,090.00 | 23.60 | 0.26% |
| CAC 40 | 7,749.39 | 14.55 | 0.19% |
| DAX 40 | 23,718.45 | 88.68 | -0.37% |
| Dow JONES (US) | 45,711.34 | 196.39 | 0.43% |
| FTSE 100 | 9,242.53 | 21.09 | 0.23% |
| HKSE | 26,246.13 | 308.00 | 1.19% |
| NASDAQ | 21,879.49 | 80.79 | 0.37% |
| Nikkei 225 | 43,765.41 | 306.12 | 0.70% |
| NZX 50 Index | 13,268.34 | 14.61 | 0.11% |
| S&P 500 | 6,512.61 | 17.46 | 0.27% |
| S&P/ASX 200 | 8,824.40 | 34.00 | 0.39% |
| SSE Composite Index | 3,813.78 | 6.49 | 0.17% |